Caduet is a fixed-dose combination of amlodipine and atorvastatin, paired in a single oral preparation for patients whose cardiovascular risk profile involves both elevated blood pressure and abnormal lipid levels. Combination products of this kind are designed to consolidate two daily medications into one — a common situation in cardiovascular prevention, where the same patient is frequently prescribed an antihypertensive and a lipid-lowering agent in parallel.
Amlodipine is classified within the antihypertensive and antianginal category, used in the management of hypertension and angina pectoris, while atorvastatin belongs to the HMG-CoA reductase inhibitor class of lipid-modifying agents, used in the management of hyperlipidemia and the broader reduction of cardiovascular risk. Caduet brings these two distinct mechanisms together so that conditions which often coexist — high blood pressure, elevated cholesterol, ischaemic heart disease, and the cardiovascular complications of diabetes — can be addressed within a single tablet rather than two separate ones. The structured indication block further down this page lists the registered uses recognised across the markets where Caduet is sold.
Caduet is registered in 39 countries, spanning Europe, Asia, North America, and parts of Africa and Latin America. Representative markets include Canada, China, Egypt, France, and Chile. Travellers and expatriates may find the same combination on pharmacy shelves under the Caduet name in some of these markets, while in others amlodipine and atorvastatin are more commonly dispensed as two separate products under different brand names.
Combination cardiovascular products vary across countries more than single-ingredient drugs, both in component ratios and in regulatory status. A local pharmacist can confirm whether an equivalent fixed-dose product exists in a given market, and any decision to start, switch, or substitute therapy is one for the prescribing healthcare provider to make alongside the patient.
